Anupam Rasayan India Ltd
Anupam Rasayan India Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.
From Anupam Rasayan India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum.
- Management optimistic about continuing growth into FY27, driven by robust pipeline and deepening global customer relationships.
- Expansion supported by scaling up commercial molecules and ramping up capacity utilization.
- Focus on ramping up Pharma and Performance Material portfolios, which showed significant growth (Pharma up 85%, Performance Materials up 245% YoY for 9MFY26).
- Pipeline includes 65+ molecules in R&D/pilot stages, supporting future revenue growth.
- Acquisition of Jayhawk Fine Chemicals to strengthen North America footprint, expanding access to innovation-driven sectors (semiconductors, automotive, pharma, EV).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention any specific current or future capex or strategic capital investment plans.
- However, it highlights the strategic acquisition of Jayhawk Fine Chemicals, a US-based specialty chemicals company, expected to close soon, which represents a significant capital investment expanding Anupam's footprint in the US.
- This acquisition strengthens supply chain presence, technology, customer base, and product portfolio across high-value sectors like semiconductors, pharma, EV, and aerospace.
- The company also focuses on ramping up capacity utilization across manufacturing assets and smoothly integrating Jayhawk, implying ongoing investments in operational expansion.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- In 9MFY26, Letters of Intent (LOIs) and contracts contributed over INR 250 crores of revenue, indicating strong conversion of the order pipeline into commercial revenue.
- The company has a robust pipeline with over 65 molecules across R&D and pilot stages in Pharma and Polymer segments.
- The Pharma segment has more than 30 molecules under development and pilot stages.
2 more points management made on order book & pipeline
Anupam Rasayan India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹636 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anupam Rasayan's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q2 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Clean Science (Q3 FY26)
Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China. Key concall takeaways from Clean…
- Aether Industri. (Q3 FY26)
The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter. Key concall…
- Kesar Petroproducts Ltd (Q3 FY26)
Export markets constitute about 40% of sales, served through 7-8 distributors across geographies. Key concall takeaways from Kesar Petroprod.'s Q3 FY26…
- Tata Chemicals Ltd (Q3 FY26)
Indian salt capacity expansion of 210 KT per annum with INR 515 crore investment is underway to meet growing demand. Key concall takeaways from Tata…
Frequently Asked Questions
What were Anupam Rasayan India Ltd Q3 FY26 results?
Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.
What is Anupam Rasayan India Ltd share price analysis?
Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anupam Rasayan India Ltd planning capital expenditure?
The transcript does not explicitly mention any specific current or future capex or strategic capital investment plans.
Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.